DB
FLXN

Dmitry Balyasny’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Dmitry Balyasny’s Portfolio FLXN Stock Details FLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-474,518
Closed -$6.24M – 1699
2020
Q2 		$6.24M Buy
+474,518
New +$4.92M 0.05% 460
2020
Q1 		– Sell
-397,107
Closed -$8.22M – 1640
2019
Q4 		$8.22M Sell
397,107
-54,932
-12% -$926K 0.05% 482
2019
Q3 		$6.2M Buy
+452,039
New +$5.36M 0.04% 505
2019
Q1 		– Sell
-15,303
Closed -$173K – 1757
2018
Q4 		$173K Sell
15,303
-2,566
-14% -$40.2K ﹤0.01% 1309
2018
Q3 		$334K Sell
17,869
-22,131
-55% -$508K ﹤0.01% 1479
2018
Q2 		$1.03M Buy
+40,000
New +$1.04M ﹤0.01% 1120
2018
Q1 		– Sell
-100,000
Closed -$2.5M – 2450
2017
Q4 		$2.5M Buy
+100,000
New +$2.45M 0.01% 1075

Other funds holding FLXN

MVP
Miller Value Partners Sarasota, Florida $423M AUM 49.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

Dmitry Balyasny's FLXN Position: Q3 2020 in Review

Dmitry Balyasny sold out of Flexion Therapeutics, Inc. (FLXN) in Q3 2020, closing a stake of 474,518 shares — an estimated $6.24M sold.

Dmitry Balyasny first reported a position in FLXN in Q4 2017 and held it in 7 quarters. The position peaked at $8.22M in Q4 2019. 135 funds tracked by Wall St. Rank hold FLXN as of Q3 2020.

  • Dmitry Balyasny reported no remaining Flexion Therapeutics, Inc. position as of Q3 2020 after selling out during the quarter.
  • Dmitry Balyasny sold 474,518 Flexion Therapeutics, Inc. shares in Q3 2020, an estimated $6.24M.
  • Dmitry Balyasny first reported a position in Flexion Therapeutics, Inc. in Q4 2017 and held it in 7 quarters.
  • Dmitry Balyasny's Flexion Therapeutics, Inc. position peaked at $8.22M in Q4 2019.
  • 135 funds tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q3 2020.

Based on Balyasny Asset Management's 13F filing for Q3 2020, filed 16 Nov 2020.